Elevated neurotrophin-3 and neurotrophin 4/5 levels in unmedicated bipolar depression and the effects of lithium

Autor(es)

Loch, Alexandre A. ^[1] ; Zanetti, Marcus V. ^{[2, 3, 1]} ; de Sousa, Rafael T. ^[1] ; Chaim, Tiffany M. ^[3] ; Serpa, Mauricio H. ^[3] ; Gattaz, Wagner F. ^{[2, 1]} ; Teixeira, Antonio L. ^[4] ; Machado-Vieira, Rodrigo ^{[2, 1, 5]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept & Inst Psychiat, Lab Neurosci, LIM 27, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Dept & Inst Psychiat, Lab Psychiat Neuroimaging, LIM 21, Sao Paulo - Brazil

^[4] Fac Med Minas Gerais, Interdisciplinary Lab Med Invest, Belo Horizonte, MG - Brazil

^[5] NIMH, ETPB, NIH, Bethesda, MD - USA

• Tipo de documento: Artigo Científico
• Fonte: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY; v. 56, p. 243-246, JAN 2 2015.
• Citações Web of Science: 11

Resumo

Background: Bipolar disorder (BD) has been associated with diverse abnormalities in neural plasticity and cellular resilience. Neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) support synaptic neuronal survival and differentiation. NT-3 and NT-4/5 levels were found to be altered in BD, potentially representing a physiological response against cellular stress. However, the use of psychopharmacological agents and heterogeneous mood states may constitute important biases in such studies. Thus, we aimed to assess NT-3 and NT-4/5 levels in medication-free BD type I or II individuals in a current depressive episode, before and after 6weeks of lithium monotherapy and matched with healthy controls. Methods: Twenty-three patients with BD type I or II during a depressive episode and 28 healthy controls were studied. Patients were required to have a 21-item Hamilton Depression Rating Scale score >= 18 and had not undergone any psychopharmacological treatment for at least 6 weeks prior to study entry. Patients were treated with lithium for 6 weeks and plasma NT-3 and NT-4/5 levels were determined at baseline and end point using ELISA method. Results: Baseline plasma levels of both NT-3 and NT-4/5 were significantly increased in acutely depressed BD subjects in comparison to healthy controls (p = 0.040 and 0.039, respectively). The NT-3 and NT-4/5 levels did not significantly change after lithium treatment. NT-3 and NT-4/5 levels were positively correlated to illness duration in BD (p = 0.032 and 0.034, respectively). Conclusion: Our findings suggest that NT-3 and NT-4/5 levels are increased in the depressive phase of BD, which seems directly associated with illness duration. The increased levels of NT-3 and NT-4/5 may underlie a biological response to cellular stress associated with the course of BD. (C) 2014 Elsevier Inc. All rights reserved. (AU)

• Processo FAPESP: 13/03905-4 - Avaliação de diferenças neurobiológicas entre pacientes com transtorno bipolar subtipos i e ii virgens de tratamento
• Beneficiário: Marcus Vinicius Zanetti
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 09/14891-9 - Avaliação longitudinal dos efeitos neuroprotetores e neurotróficos induzidos pelo lítio no transtorno bipolar: identificação de alvos clinicamente relevantes
• Beneficiário: Rodrigo Machado-Vieira
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores